A neurodegenerative disorder is a condition that causes a degeneration of neurons in the central nervous system, leading to cognitive impairment and movement disorders. An accumulation of oxidative stress in neurons contributes to the pathogenesis of neurodegenerative disorders. Over the past few years, several studies have suggested that short‐chain fatty acids, metabolites of the gut microbiota, might have a beneficial effect in neurodegenerative disorders. A G protein‐coupled receptor 43 (GPR43) plays an important role in modulating oxidative stress and inflammatory processes in several tissues. Interestingly, the downstream signaling pathways activated by GPR43 to modulate oxidative stress differ among tissues. Moreover, the cellular mechanisms underlying GPR43 activation in neuronal cells to handle oxidative stress remain unclear. In this present study, we tested the role of GPR43, which is activated by short‐chain fatty acids or a specific GPR43 agonist, in an oxidative stress‐induced neuronal cell line (SH‐SY5Y) injury. Our findings suggest that a combination of short‐chain fatty acids with a physiological function could protect neurons from H2O2‐induced cell damage. The effect of short‐chain fatty acids mixture was abolished by pretreatment with a GPR43 antagonist, indicating this protective effect is a GPR43‐dependent mechanism. In addition, a specific GPR43 agonist shows a similar result to that found in short‐chain fatty acids mixture. Furthermore, our findings indicate that the downstream activation of GPR43 to protect against oxidative stress‐induced neuronal injury is a biased Gq activation signaling of GPR43, which results in the prevention of H2O2‐induced neuronal apoptosis. In conclusion, our results show new insight into the cellular mechanism of GPR43 and its neuroprotective effect. Taken together, this newly discovered finding suggests that activation of the biased Gq signaling pathway of GPR43 might be a potential therapeutic target for aging‐related neurodegeneration. image
The cytoskeletal protein filamin A (FLNA) has been suggested to play an important role in the responsiveness of GH-secreting pituitary tumors to somatostatin receptor subtype 2 (SSTR2) agonists by regulating SSTR2 expression and signaling. However, the underlying mechanisms are unknown. In this study, we use fast multicolor single-molecule microscopy to image individual SSTR2 and FLNA molecules at the surface of living cells with unprecedented spatiotemporal resolution. We find that SSTR2 and FLNA undergo transient interactions, which occur preferentially along actin fibers and contribute to restraining SSTR2 diffusion. Agonist stimulation increases the localization of SSTR2 along actin fibers and, subsequently, SSTR2 clustering and recruitment to clathrin-coated pits (CCPs). Interfering with FLNA–SSTR2 binding with a dominant-negative FLNA fragment increases SSTR2 mobility, hampers the formation and alignment of SSTR2 clusters along actin fibers, and impairs both SSTR2 recruitment to CCPs and SSTR2 internalization. These findings indicate that dynamic SSTR2–FLNA interactions critically control the nanoscale localization of SSTR2 at the plasma membrane and are required for coupling SSTR2 clustering to internalization. These mechanisms explain the critical role of FLNA in the control of SSTR2 expression and signaling and suggest the possibility of targeting SSTR2–FLNA interactions for the therapy of pharmacologically resistant GH-secreting pituitary tumors.
Binge eating disorder (BED) is a prevalent eating disorder lacking adequate pharmacological interventions. This review examines the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs), medications approved for type 2 diabetes and obesity now being investigated for eating disorders through their modulation of metabolic and reward pathways. A narrative review was conducted using PubMed/MEDLINE, through May 2025, to examine GLP-1RA effects on BED, including preclinical and clinical studies, mechanistic investigations, and relevant reviews. GLP-1 receptors (GLP-1Rs) are expressed in hypothalamic nuclei, regulating energy homeostasis and mesolimbic circuits controlling food reward. Preclinical studies demonstrate that GLP-1RAs reduce food-seeking behavior, suppress dopamine signaling in reward circuits, and modulate neural transmission in key brain regions. These effects extend beyond appetite suppression to directly modify reward processing underlying compulsive eating. Emerging clinical evidence with semaglutide and liraglutide report reductions in binge eating episodes, decreased food cravings, and improved symptom scores. However, current studies remain small-scale with methodological limitations, and translating findings from animal models to human eating disorder complexity presents significant challenges. This review integrates preclinical and clinical evidence demonstrating that GLP-1RAs modulate both metabolic and reward pathways. By elucidating the underlying neurobiological mechanisms, GLP-1RAs may offer advantages over current symptom-focused therapies for BED.
Diabetic nephropathy (DN) is a leading cause of end-stage renal disease. An elevated fatty acid plasma concentration leads to podocyte injury and DN progression. This study aimed to identify and characterize cellular mechanisms of natural compounds that inhibit palmitic acid (PA)–induced human podocyte injury. By screening 355 natural compounds using a cell viability assay, 3-hydroxyterphenyllin (3-HT) and candidusin A (CDA), isolated from the marine-derived fungus Aspergillus candidus PSU-AMF169, were found to protect against PA-induced podocyte injury, with half-maximal inhibitory concentrations (IC50) of ~16 and ~18 µM, respectively. Flow cytometry revealed that 3-HT and CDA suppressed PA-induced podocyte apoptosis. Importantly, CDA significantly prevented PA-induced podocyte barrier impairment as determined by 70 kDa dextran flux. Reactive oxygen species (ROS) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) direct scavenging assays indicated that both compounds exerted an anti-oxidative effect via direct free radical–scavenging activity. Moreover, 3-HT and CDA upregulated the anti-apoptotic Bcl2 protein. In conclusion, 3-HT and CDA represent fungus-derived bioactive compounds that have a novel protective effect on PA-induced human podocyte apoptosis via mechanisms involving free radical scavenging and Bcl2 upregulation.
Background: Medical schools that use multiple admission pathways may admit students with varying research-related experiences and opportunities. We examined the association between admission pathway and documented extracurricular research participation during medical training and explored stakeholder perspectives to contextualize participation and non-participation. Methods: We conducted a single-institution sequential explanatory mixed-methods study at a Thai medical school. Institutional records from 1,021 students admitted during 2017–2022 through portfolio-based (TCAS1) or examination-based (TCAS3) pathways were analyzed. The quantitative outcome was at least one eligible extracurricular research grant, conference abstract presentation, or scholarly publication recorded from entry until graduation or 30 September 2023, whichever occurred first. Mandatory curricular and concurrent-degree research were excluded. Logistic regression comprised a minimally adjusted model of pathway and cohort, a primary model additionally adjusted for selected pre-admission characteristics, and paired complete-case models with and without pre-university grade point average (GPA). For qualitative sampling, the same eligibility criteria were applied to records through 30 September 2024. Interviews with 24 students or graduates, three faculty advisors, and three research-support committee members were analyzed thematically and integrated with quantitative findings. Results: Overall, 103/1,021 students (10.1%) had documented participation: 52/246 TCAS1 students (21.1%) and 51/775 TCAS3 students (6.6%). In the primary adjusted model, TCAS1 admission was associated with documented participation (adjusted odds ratio 9.19, 95% confidence interval 4.96–17.03). Among 854 students with available pre-university GPA, the pathway estimate was 11.25 (5.36–23.63) before and 10.63 (5.02–22.51) after GPA adjustment. The GPA estimate was imprecise and not statistically significant. Interview accounts highlighted prior exposure and research self-efficacy, mentoring and visible entry routes, competing priorities, academic pressure, and unclear pathways. Contrasting cases indicated that prior exposure was neither necessary nor sufficient for participation. Conclusions: Admission pathway was associated with documented extracurricular research participation but should not be interpreted as causal or as a proxy for student potential. The association may partly reflect different research-related starting conditions, while post-admission opportunities and constraints were also relevant. Research opportunities should be visible and accessible across admission groups while respecting diverse student priorities.